高危急性髓系白血病异基因造血干细胞移植后复发的防治  

Prevention and treatment of high-risk acute myeloid leukemia recurrence after allogeneic hematopoietic stem cell transplantation

作　　者：王佳琦 盛新歌 马志豪 鹿全意[2] Wang Jiaqi;Sheng Xinge;Ma Zhihao;Lu Quanyi(Graduate School of Xiamen University Medical College,Xiamen 361102,China;不详)

机构地区：[1]厦门大学医学院研究生院,厦门361102 [2]厦门大学附属中山医院血液科

出　　处：《器官移植》2023年第3期364-370,共7页Organ Transplantation

基　　金：福建省科技计划项目引导性项目(2019D009);厦门市医疗卫生厅指导项目(3502Z20199174)。

摘　　要：急性髓系白血病(AML)是一组高度异质性的克隆性疾病,化学药物治疗和造血干细胞移植均为治疗AML的方法。对于高危AML患者而言,异基因造血干细胞移植为治疗该疾病的有效手段,但部分AML患者造血干细胞移植后仍可能面临疾病复发的问题,大多数复发患者再行化学药物治疗、二次移植等的效果不佳,是导致患者异基因造血干细胞移植后死亡的主要原因。因此,加强对异基因造血干细胞移植后AML患者的随访,并采取一些合适的手段预防移植后复发显得尤为重要。本文就高危AML患者异基因造血干细胞移植后复发的监测、药物治疗和细胞治疗进行综述,以期为改善高危AML患者异基因造血干细胞移植预后提供参考。Acute myeloid leukemia(AML)is a group of highly-heterogeneous clonal diseases.Chemotherapy and hematopoietic stem cell transplantation are considered as effective treatment for AML.For high-risk AML patients,allogeneic hematopoietic stem cell transplantation is an effective therapeutic option.However,some AML patients may still face the problem of disease recurrence after hematopoietic stem cell transplantation.A majority of recurrent patients cannot be effectively treated by chemotherapy or secondary transplantation,which is the main cause of death after allogeneic hematopoietic stem cell transplantation.Therefore,it is of significance to strengthen follow-up of AML patients after allogeneic hematopoietic stem cell transplantation and implement appropriate measures to prevent postoperative recurrence.In this article,the monitoring,drug prevention and cell therapy of recurrence after allogeneic hematopoietic stem cell transplantation in high-risk AML patients were reviewed,aiming to provide reference for improving clinical prognosis of high-risk AML patients undergoing allogeneic hematopoietic stem cell transplantation.

关 键 词：急性髓系白血病 高危 异基因造血干细胞移植 微小残留病灶 复发 去甲基化药物 移植物抗宿主病 移植物抗白血病 

分 类 号：R617[医药卫生—外科学] R552[医药卫生—临床医学]